Coping with viral diversity in HIV vaccine design: A response to Nickle et al. [1]

PLoS Computational Biology

Volumn 4, Issue 1, 2008, Pages 0175-0178

  Fischer, Will ^a   Liao, H X ^c   Haynes, Barton F ^c   Letvin, Norman L ^d   Korber, Bette ^b  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b SANTA FE INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINES;

HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ETHANOLAMINE DERIVATIVE; NEF PROTEIN; SR 58339A;

ANTIGEN PRESENTATION; CENTER OF TREE SEQUENCE; COMPUTER MODEL; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LETTER; MOSAIC METHOD; STRAIN IDENTIFICATION; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINE PRODUCTION; ANTIGENIC VARIATION; DRUG DESIGN; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; METHODOLOGY; NOTE;

AIDS VACCINES; ANTIGENIC VARIATION; DRUG DESIGN; EPITOPE MAPPING; ETHANOLAMINES; GENE PRODUCTS, NEF; GENETIC VARIATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 38949169587     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0040015     Document Type: Letter

References (8)

1. Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, et al. (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 3: e75. doi:10.1371/journal.pcbi.0030075
2. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
3. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, et al. (2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893-6904.
4. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, et al. (2003) Consensus and ancestral state HIV vaccines. Letter in response to Gaschen et al. [5]. Science 299: 1515-1518.
5. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
6. Jojic N, Jojic V, Frey B, Meek C, Heckerman D (2005) Using "epitomes" to model genetic diversity: Rational design of HIV vaccine cocktails. In: Weiss Y, Schölkopf B, Platt J, editors. Vancouver (British Columbia): MIT Press. 587-594.
7. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, et al. (2004) Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78: 2187-2200.
8. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.